PRO051 clinical trials
Also written Drisapersen and GSK2402968.
How each study uses PRO051 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses PRO051 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular DystrophyCompletedPhase 3GlaxoSmithKlineNCT01254019Written as GSK2402968 6mg/kg/week
- A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian SubjectsTerminatedPhase 3BioMarin PharmaceuticalNCT01803412Written as Drisapersen
- A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)CompletedPhase 2GlaxoSmithKlineNCT01462292Written as GSK2402968 3mg/kg/week
- Open Label Study of GSK2402968 in Subjects With Duchenne Muscular DystrophyTerminatedPhase 3GlaxoSmithKlineNCT01480245Written as GSK2402968
- A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of AdministrationTerminatedPhase 2BioMarin PharmaceuticalNCT01910649Written as Drisapersen
- Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular DystrophyCompletedPhase 2GlaxoSmithKlineNCT01153932Written as GSK2402968
- Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment ProtocolWithdrawnPhase 3GlaxoSmithKlineNCT01890798Written as Drisapersen